Embecta Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Dev Kurdikar

Algemeen directeur

US$7.5m

Totale compensatie

Percentage CEO-salaris	11.6%
Dienstverband CEO	2.6yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Dev Kurdikar's beloning veranderd ten opzichte van Embecta's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$70m
Mar 31 2024	n/a	n/a	US$70m
Dec 31 2023	n/a	n/a	US$55m
Sep 30 2023	US$7m	US$863k	US$70m
Jun 30 2023	n/a	n/a	US$47m
Mar 31 2023	n/a	n/a	US$94m
Dec 31 2022	n/a	n/a	US$160m
Sep 30 2022	US$11m	US$791k	US$224m
Jun 30 2022	n/a	n/a	US$338m
Mar 31 2022	n/a	n/a	US$380m
Dec 31 2021	n/a	n/a	US$408m
Sep 30 2021	US$3m	US$447k	US$415m

Compensatie versus markt: De totale vergoeding ($USD 7.46M ) Dev } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Dev is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Dev Kurdikar (55 yo)

2.6yrs

Tenure

US$7,464,497

Compensatie

Mr. Devdatt Kurdikar, also known as Dev, is a Director at Zimmer Biomet Holdings, Inc since June 2024. He serves as Chief Executive Officer and Director at Embecta Corp. since April 01, 2022 and serves as...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Devdatt Kurdikar	President	2.6yrs	US$7.46m	0.67% € 5.2m
Claire Pomeroy	Independent Director	2.6yrs	US$293.02k	0.046% € 355.5k
Christopher Reidy	Director	2.6yrs	US$288.02k	0.056% € 435.4k
Robert Hombach	Independent Director	2.7yrs	US$288.02k	0.043% € 334.8k
David Melcher	Independent Non-Executive Chairman	2.6yrs	US$459.97k	0.078% € 606.1k
Milton Morris	Independent Director	2.6yrs	US$277.02k	0.043% € 334.0k
David Albritton	Independent Director	2.6yrs	US$272.27k	0.023% € 180.8k
Karen Prange	Independent Director	2.6yrs	US$288.02k	0.023% € 180.8k
Carrie Anderson	Independent Director	2.6yrs	US$272.02k	0.023% € 180.8k

2.6yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van JX7 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.6 jaar), wat duidt op een nieuw bestuur.

Embecta Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Embecta Corp., Annual General Meeting, Feb 07, 2024

Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023

Independent Non-Executive Chairman recently bought €96k worth of stock

Independent Non-Executive Chairman recently bought €94k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Embecta Corp. to Report Q4, 2024 Results on Nov 26, 2024

Investor sentiment improves as stock rises 17%

Embecta Corp. Receives 510(k) Clearance from the U.S. Food and Drug Administration for Disposable Insulin Delivery System

Investor sentiment improves as stock rises 16%

Upcoming dividend of US$0.15 per share

Third quarter dividend of US$0.15 announced

Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.27 in 3Q 2023)

Embecta Corp. Revises Earnings Guidance for the Fiscal Year 2024

New major risk - Share price stability

Embecta Corp. to Report Q3, 2024 Results on Aug 09, 2024

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 30%

Second quarter dividend of US$0.15 announced

New major risk - Revenue and earnings growth

Embecta Corp. Provides Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings released: EPS: US$0.50 (vs US$0.24 in 2Q 2023)

Embecta Corp. to Report Q2, 2024 Results on May 09, 2024

Investor sentiment deteriorates as stock falls 18%

Upcoming dividend of US$0.15 per share

Investor sentiment deteriorates as stock falls 26%

First quarter dividend of US$0.15 announced

First quarter 2024 earnings released: EPS: US$0.35 (vs US$0.62 in 1Q 2023)

New major risk - Revenue and earnings growth

Embecta Corp. Updates Earnings Guidance for the Fiscal Year 2024

Embecta Corp. to Report Q1, 2024 Results on Feb 09, 2024

Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch Pump

Embecta Corp., Annual General Meeting, Feb 07, 2024

Full year 2023 earnings released: EPS: US$1.23 (vs US$3.92 in FY 2022)

Embecta Corp. to Report Q4, 2023 Results on Nov 21, 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Upcoming dividend of US$0.15 per share at 3.2% yield

Third quarter 2023 earnings released: EPS: US$0.27 (vs US$1.08 in 3Q 2022)

Embecta Corp. Revises Earnings Guidance for the Fiscal Year 2023

Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023

Second quarter 2023 earnings released: EPS: US$0.24 (vs US$1.38 in 2Q 2022)

Embecta Corp. Revises Revenue Guidance for the Fiscal Year 2023

Independent Non-Executive Chairman recently bought €96k worth of stock

Independent Non-Executive Chairman recently bought €94k worth of stock

Embecta Corp. Declares Quarterly Cash Dividend, Payable on March 13, 2023

First quarter 2023 earnings released

Investor sentiment improves as stock rises 15%

Embecta Corp. to Report Q1, 2023 Results on Feb 14, 2023

Investor sentiment deteriorated over the past week

Full year 2022 earnings released

Embecta Corp. Provides Revenue Guidance for the Fiscal Year 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Embecta Corp., Annual General Meeting, Feb 09, 2023

Embecta Corp.(NasdaqGS:EMBC) dropped from FTSE All-World Index (USD)

Third quarter 2022 earnings released

Embecta Corp. Revises Revenue Guidance for the Second-Half Fiscal Year 2022

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd